Cardiovascular Disease and Rheumatoid Arthritis: An Update

Charles‐Schoeman, Christina

doi:10.1007/s11926-012-0271-5

Cited by 43 publications

(33 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Care gaps might be due to under‐recognition and under‐assessment of CV risk in RA patients as well as a lack of care coordination between primary care physicians (PCPs) and rheumatologists . These studies raise the question whether under‐treatment of traditional CV risk factors may contribute to the increased CV burden in RA . However, most of these studies are limited by small sample size , the lack of a comparison group , or no access to laboratory test results and blood pressure measurements to confirm under‐treatment .…”

Section: Introductionmentioning

confidence: 99%

Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting

Cheetham

Reynolds

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To compare traditional cardiovascular (CV) risk factor management among patients with rheumatoid arthritis (RA) to that of matched non-RA controls within a large US managed care setting. Methods. Adult patients with RA and age-and sex-matched general population (general controls) or osteoarthritis (OA) controls were identified between January 1, 2007 and December 31, 2011. We compared health care utilization, measurement, treatment, and treatment target achievement of traditional CV risk factors among subgroups of CV comorbidity during 1 year of followup between RA and controls. ; however, a target LDL level was more likely to be achieved in RA compared to general controls (OR 1.27 [95% CI 1.17-1.37]) as well as target levels of BP and hemoglobin A 1c . These results were consistent with results for OA controls except for a lower probability of receiving a statin in RA compared to OA. Conclusion. Traditional CV risk factors in patients with RA were not less aggressively managed compared to non-RA controls.

show abstract

Section: Introductionmentioning

confidence: 99%

Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting

Cheetham

Reynolds

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Studies confirm the increased risk of cardiovascular diseases in RA [4][5][6][7]. The cardiovascular complications-beside renal and pulmonary ones -are important in the mortality of SSc patients as well [8][9][10].…”

Section: Introductionmentioning

confidence: 82%

Complications and Mortality in Systemic Vasculitis – Vasculogenic Clinicopathologic Entities in Rheumatoid Arthritis and Progressive Systemic Sclerosis Autopsy Patients

Bély¹,

Apáthy²

2017

J Vasc

View full text Add to dashboard Cite

“…Interestingly, in addition to being an indicator of frailty, grip strength has been shown to be a predictor of a wide range of adverse health outcomes 53 , e.g., cardiovascular disease, which RA patients are at increased risk of developing 54 and that are impacted by the microbiome 49,55 . Thus, to address whether the protection afforded by ES-62 is associated modulation of the gut microbiota, a metagenomic approach was used to profile the bacterial populations present in the intestines of CIA-mice, exposed or not to ES-62.…”

Section: Es-62 Protection Against Cia Is Associated With Normalisatiomentioning

confidence: 99%

The parasitic worm product ES-62 normalises the gut microbiota/bone marrow axis in inflammatory arthritis

Doonan

Tarafdar

Pineda

et al. 2018

Preprint

View full text Add to dashboard Cite

The human immune system has evolved in the context of our colonisation by bacteria, viruses, fungi and parasitic helminths. Reflecting this, the rapid eradication of pathogens appears to have resulted in reduced microbiome diversity and generation of chronically activated immune systems, presaging the recent rise of allergic, autoimmune and metabolic disorders. Certainly, gastrointestinal helminths can protect against gut and lung mucosa inflammatory conditions by modulating the microbiome and suppressing the chronic inflammation associated with dysbiosis. Here, we employ ES-62, an immunomodulator secreted by tissue-dwelling Acanthocheilonema viteae to show that modulation of the gut microbiome does not require live infection with gastrointestinal-based helminths nor is protection restricted to mucosal diseases.Specifically, subcutaneous administration of this defined parasitic worm product affords protection against joint disease in collagen-induced arthritis, a mouse model of rheumatoid arthritis, which is associated with normalisation of gut microbiota and prevention of loss of intestinal barrier integrity.

show abstract

Cardiovascular Disease and Rheumatoid Arthritis: An Update

Cited by 43 publications

References 68 publications

Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting

Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting

Complications and Mortality in Systemic Vasculitis – Vasculogenic Clinicopathologic Entities in Rheumatoid Arthritis and Progressive Systemic Sclerosis Autopsy Patients

The parasitic worm product ES-62 normalises the gut microbiota/bone marrow axis in inflammatory arthritis

Contact Info

Product

Resources

About